Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients

NCT02143622 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

BIOLOGICAL: LJM716
BIOLOGICAL: cetuximab

Sponsor

Novartis Pharmaceuticals